Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Durr, Megan L ^a   Mydlarz, Wojciech K ^a   Shao, Chunbo ^a   Zahurak, Marianna L ^a   Chuang, Alice Y ^a   Hoque, Mohammad O ^a   Westra, William H ^a   Liegeois, Nanette J ^a   Califano, Joseph A ^a,b   Sidransky, David ^a   Ha, Patrick K ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENT IN MELANOMA 1; APC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DELETED IN COLORECTAL CARCINOMA; FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; GLUTATHIONE TRANSFERASE P1; HYPERMETHYLATED IN CANCER 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLATED IN TUMOR 1; MISMATCH REPAIR PROTEIN; ONCOPROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; STRATIFIN; TARGET OF METHYLATION INDUCED SILENCING 1; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CPG ISLAND; DNA EXTRACTION; DNA ISOLATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; SALIVARY GLAND TUMOR; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

MENTHA;

EID: 77956534309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010828     Document Type: Article

References (53)

1. Johns ME, Goldsmith MM (1989) Incidence, diagnosis, and classification of salivary gland tumors. Part 1. Oncology (Williston Park) 3: 47-56; discussion 56, 58, 62.
2. Johns ME, Goldsmith MM (1989) Current management of salivary gland tumors. Part 2. Oncology (Williston Park) 3: 85-91; discussion 94, 99.
3. Lalami Y, Vereecken P, Dequanter D, Lothaire P, Awada A (2006) Salivary glands carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. Curr Opin Oncol 18: 258-265.
4. Zhang CY, Mao L, Li L, Tian Z, Zhou XJ, et al. (2007) Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 110: 87-95.
5. Kishi M, Nakamura M, Nishimine M, Ikuta M, Kirita T, et al. (2005) Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. Oral Oncol 41: 161-169.
6. Spiro RH, Huvos AG, Strong EW (1974) Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128: 512-520.
7. Uchida D, Begum NM, Almofti A, Kawamata H, Yoshida H, et al. (2004) Frequent downregulation of 14-3-3 sigma protein and hypermethylation of 14-3-3 sigma gene in salivary gland adenoid cystic carcinoma. Br J Cancer 91: 1131-1138.
8. Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104: 771-776.
9. el-Naggar AK, Hurr K, Kagan J, Gillenwater A, Callender D, et al. (1997) Genotypic alterations in benign and malignant salivary gland tumors: histogenetic and clinical implications. Am J Surg Pathol 21: 691-697.
10. Cerilli LA, Swartzbaugh JR, Saadut R, Marshall CE, Rumpel CA, et al. (1999) Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. Hum Pathol 30: 1242-1246.
11. Nishimine M, Nakamura M, Kishi M, Okamoto M, Shimada K, et al. (2003) Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. Oncol Rep 10: 555-560.
12. Esteller M (2005) Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 205: 172-180.
13. Esteller M, Herman JG (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196: 1-7.
14. Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, et al. (2008) Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res 14: 2664-2672.
15. Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, et al. (2004) Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn 6: 180-190.
16. Maruya S, Kurotaki H, Shimoyama N, Kaimori M, Shinkawa H, et al. (2003) Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec 65: 26-32.
17. Maruya S, Kurotaki H, Wada R, Saku T, Shinkawa H, et al. (2004) Promoter methylation and protein expression of the E-cadherin gene in the clinicopath-ologic assessment of adenoid cystic carcinoma. Mod Pathol 17: 637-645.
18. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, et al. (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12: 7353-7358.
19. Guo XL, Sun SZ, Wang WX, Wei FC, Yu HB, et al. (2007) Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands. Int J Oral Maxillofac Surg 36: 350-353.
20. Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, et al. (2006) TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 207: 654-659.
21. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, et al. (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10: 8472-8478.
22. Ha PK, Califano JA (2006) Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82.
23. Fukasawa M, Kimura M, Morita S, Matsubara K, Yamanaka S, et al. (2006) Microarray analysis of promoter methylation in lung cancers. J Hum Genet 51: 368-374.
24. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, et al. (2005) PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65: 4963-4968.
25. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, et al. (2003) Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9: 1370-1375.
26. Armitage P (1955) Test for linear trend in proportions and frequencies. Biometrics 11: 375-396.
27. Cuzick J (1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90.
28. (1985) SAS User's Guide. Version 5 ed. Cary, NC: SAS Institute Inc.
29. (1997) StatXact 4 for windows. Version 4 ed. Cambridge, MA: Cytel Software Corporation.
30. (2004) R: A language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing.
31. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, et al. (2008) Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 179: 346-352.
32. Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, et al. (2007) Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133: 1131-1138.
33. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, et al. (2007) High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 13: 6122-6129.
34. Safar AM, Spencer H, 3rd, Su X, Coffey M, Cooney CA, et al. (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11: 4400-4405.
35. Daa T, Kashima K, Kaku N, Suzuki M, Yokoyama S (2004) Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol 17: 1475-1482.
36. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, et al. (2002) Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8: 3164-3171.
37. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, et al. (2001) Methylation profiling in acute myeloid leukemia. Blood 97: 2823-2829.
38. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, et al. (2003) CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22: 924-934.
39. An C, Choi IS, Yao JC, Worah S, Xie K, et al. (2005) Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11: 656-663.
40. Bittencourt Rosas SL, Caballero OL, Dong SM, da Costa Carvalho Mda G, Sidransky D, et al. (2001) Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 170: 73-79.
41. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, et al. (2004) Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 64: 5982-5987.
42. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, et al. (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742.
43. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, et al. (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119: 1338-1344.
44. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407-415.
45. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, et al. (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798-802.
46. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
47. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, et al. (2008) Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep 20: 1489-1495.
48. Hoque MO, Begum S, Brait M, Jeronimo C, Zahurak M, et al. (2008) Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 179: 743-747.
49. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, et al. (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895.
50. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, et al. (2006) Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98: 996-1004.
51. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, et al. (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11: 8321-8325.
52. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
53. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, et al. (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938.